

398 W. Grand Avenue | Rahway, NJ 07065
Ph 844-527-9486 | Fx 866-285-7628
NPI# 1669881777 NABP# 3148839
info@pfsprx.com PFSPrx.com



Phone Order
Ship to Patient: Home Work
Ship to: Physician Office
 Nurse / Training
 PFSP Pharmacy

Patient Name _____ Date of Birth _____ Male Female
Address _____ Apt # _____ City _____ State _____ Zip _____
Telephone _____ Cell _____ SSN _____ Email _____
Allergies _____ Comorbidities _____
Current Medications (if necessary, please fax a complete list) _____

Primary Insurance _____ ID# _____ Group # _____
Insured's Name _____ Employer _____
City _____ State _____ Phone _____

ICD-10 Diagnosis Code: L40.59 Psoriatic Arthritis M32.10 SLE M06.9 Rheumatoid Arthritis M45.9 Ankylosing Spondylitis M35.2 - Behçet's Disease
 M19.90 Osteoarthritis, unspecified site M81.0 Age-related osteoporosis w/o current fracture Other _____
Previously treated for this condition? Yes No Medication(s) failed _____
Patient currently taking Methotrexate? Yes No For Humira/Enbrel: PPD (TB Test) Results _____ Date _____ Total Swollen Joints _____
Rheumatoid Factor Positive _____ For Forteo: T-Score _____ Date _____ Fracture History: Site _____ Date _____

PRESCRIPTION PLEASE ATTACH COPIES OF PATIENT'S INSURANCE CARDS

HUMIRA® PEN 40mg/0.8 mL HUMIRA® PFS 40mg/0.8 mL
 HUMIRA® Citrate-Free PEN 40mg/0.4 mL HUMIRA® Citrate-Free PFS 40mg/0.4 mL
SIG: Inject 40mg SQ every OTHER week | Inject 40mg SQ ONCE a week
QTY: _____ Refill: _____ If applicable, enroll patient in Ambassador Program

ENBREL® SureClick™ Autoinjector 50mg PFS 25mg PFS 50mg
 Multiuse Vial 25mg (injection supplies included) Enbrel Mini™/AutoTouch 50mg
SIG: 50mg once weekly 25mg twice weekly QTY: 4 week supply Refill: _____
 If applicable, enroll patient in ENBREL Support™

CIMZIA® 200mg/1ml PFS PFS Starter Kit If applicable, enroll patient in CIMPlicity®
 Initial Dose: Inject 400mg SQ on day 1, at week 2 & at week 4
 Maintenance Dose: Inject 200mg SQ every OTHER week QTY: _____ Refill: _____
 Maintenance Dose: Inject 400mg SQ every 4 weeks QTY: _____ Refill: _____
 Other _____ QTY: _____ Refill: _____

SIMPONI® SmartJect™ PEN 50mg/0.5mL PFS 50mg/0.5mL
 Inject 50mg subcutaneously once per month QTY: 1 month supply Refills: _____

SIMPONI ARIA™ 50mg/4ml (12.5mg/ml) in a single use vial
 Inject 2mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks
Patient Weight (kg): _____ QTY: _____ # of vials Refills: _____
 If applicable, enroll patient in SimponiOne®

REMICADE® 100mg Vial Dose: 5mg/kg _____ mg/kg Patient Weight (kg): _____
 IV on weeks 0, 2 and 6 (Induction) QTY: _____ # of vials Refills: 0
 IV every 8 weeks (Maintenance Dose) QTY: _____ # of vials Refills: _____
 IV every _____ weeks QTY: _____ # of vials Refills: _____
 If applicable, enroll patient in Janssen CarePath

RINVOQ™ 15mg tablet SIG: Take one tablet by mouth once daily QTY: 30 Refill: _____
 OLUMIANT® 2mg tablet SIG: Take one tablet by mouth once daily QTY: 30 Refill: _____
 XELJANZ® 5mg tablet SIG: Take one tablet by mouth twice daily QTY: 60 Refill: _____
 XELJANZ XR® 11mg tablet SIG: Take one tablet by mouth once daily QTY: 30 Refill: _____
If applicable, enroll patient in myAbbVie Assist (Rinvoq) Lilly Cares (Olumiant) XELSOURCE SM

DUEXIS (ibuprofen 800mg/famotidine 26.6mg) tablet
 SIG: Take 1 tablet by mouth three times daily QTY: 90 Refill: _____
 RAYOS 1mg 2mg 5mg SIG: _____ QTY: _____ Refill: _____
 PENNSAID 2% SOLUTION 112g pump bottle
 SIG: Apply 2 pumps to the affected joint twice daily QTY: _____ Refill: _____
 RELAFEN DS 1000mg tablet
 SIG: 1 PO QD QTY: 30 Refill: _____ SIG: 1 PO BID QTY: 60 Refill: _____

KEVZARA® 200 mg/1.14 mL | 150 mg/1.14 mL Pre-filled Pens Pre-filled Syringes
Dispense: Inject 150 mg subcutaneously every other week QTY: 2 Refill: _____
 Inject 200 mg subcutaneously every other week QTY: 2 Refill: _____
ANC _____ Platelets _____ Liver Function Tests _____
 If applicable, enroll patient in KevzaraConnect®

ACTEMRA® ACTPen 162mg/0.9mL PFS 162mg/0.9mL Vial 400mg/20mL
Dosing: < 100kg: Inject 162mg once every other week QTY: _____ Refills: _____
 ≥ 100kg: Inject 162mg once every week QTY: _____ Refills: _____
 IV: Infuse 4mg/kg IV once every four weeks QTY: _____ Refills: _____
 Other: _____ QTY: _____ Refills: _____
 If applicable, enroll in Actemra Access Solutions

TYMLOS™ 1.56 mL Prefilled Multi-Dose Pen QTY: 1 pen (30 day supply) Refill: _____
 Inject 80mcg subcutaneously once a day If applicable, enroll patient in Together with Tymlos

FORTEO® 600mcg/2.4ml Pen If applicable, enroll patient in FORTEO Connect
 Inject 20mcg subcutaneously Daily as directed QTY: 4 week supply Refill: _____
 BD - 31G x 5mm PEN NEEDLES use as directed w/Forteo pen QTY: 100 (1 box) Refill: _____

PROLIA® 60mg PFS If applicable, enroll patient in ProliaPlus®
 Inject 60mg subcutaneously every 6 months QTY: 1 Refill: _____

RECLAST® 5mg/100ml Vial 5mg IV once yearly QTY: 1 Refill: _____

EVENITY® 105mg/1.17mL PFS (2-count)
 Inject 210mg (2-105mg PFS) under the skin once monthly for 12 months
QTY: 2 PFS (1 month) 6 PFS (3 months) Refill: _____

METHOTREXATE TABS RASUVO OTREXUP If applicable, enroll patient in CORE Connections
 SQ: Inject _____ mg SQ once weekly QTY: _____ Refill: _____
 Oral: Take _____ mg by mouth once weekly QTY: _____ Refill: _____
 Other: _____ QTY: _____ Refill: _____

KINERET® 100mg/0.67 mL PFS If applicable, enroll patient in KINERET On TRACK
 Inject 100mg (0.67mL) SQ QD QTY: 4 week supply Refill: _____

ORENCIA® Carton of 4 autoinjectors: 125mg PFS 250mg Vial 125mg ClickJect™
 Inject 125mg SQ weekly
 < 60kg Infuse 500mg at weeks 0, 2 and 4, then every 4 weeks thereafter
 60 - 100kg Infuse 750mg at weeks 0, 2 and 4, then every 4 weeks thereafter
 > 100kg Infuse 1000mg at weeks 0, 2 and 4, then every 4 weeks thereafter
 Other: _____
QTY: 4 week supply Refill: _____ If applicable, enroll patient in ORENCIA On Call™

RITUXAN® 100mg/10ml Vial 500mg/50ml Vial QTY: _____ # of vials Refill: _____
 Infuse 1000mg on day 1 and day 15, repeat course every 24 weeks
 Other: _____

OTEZLA® Prescriber provided Two-Week Starter Pack on Starter: 28 Day Starter Pack SIG: Take as directed QTY: 55 Refill: 0
 30mg twice daily (recommended) 30mg daily (for severe renal impairment)
Maintenance: SIG: Take one tablet by mouth twice daily QTY: 60 Refill: _____
 SIG: Take one tablet by mouth daily QTY: 30 Refill: _____
 If applicable, enroll in Otezla SupportPlus™ If applicable, enroll in Bridge RX Program

COSENTYX® 150 mg Sensoready® Pen 150 mg PFS If applicable, enroll patient in Cosentyx® Connect
 Starting Dose: Weeks 0, 1, 2, 3, and 4, then once every 4 weeks
SIG: Inject 150 mg dose SQ once weekly for 5 weeks. QTY: 5 injection devices Refills: 0
 _____ mg dose SQ once weekly for 5 weeks. QTY: 10 injection devices Refills: 0
Each 300 mg dose is given as 2 SQ injections of 150 mg.
 Maintenance Supply: Once every 4 weeks
SIG: Inject 150 mg dose SQ once every 4 weeks QTY: _____ Refills: _____
 Inject 300 mg dose SQ once every 4 weeks QTY: _____ Refills: _____
Each 300 mg dose is given as 2 SQ injections of 150 mg.

STELARA™ 45mg PFS 90mg PFS Patient Weight (kg): _____
 For patients <100kg (220lbs): Inject 45mg SQ initially & 4 weeks later, followed by 45mg every 12 weeks.
 For patients >100kg (220lbs): Inject 90mg SQ initially & 4 weeks later, followed by 90mg every 12 weeks.
 Other: _____ QTY: _____ Refill: _____
 If applicable, enroll patient in Janssen CarePath

TALTZ® 80mg Autoinjector Prefilled Syringe
 Starting Dose: Inject 160mg SQ at week 0 followed by 80mg at week 4
 Maintenance Dose: Inject 80mg SQ every 4 weeks QTY: _____ Refills: _____
 Sharps Container If applicable, enroll patient in Taltz Together™

BENLYSTA® 120mg Vial 400mg Vial Patient Weight (kg): _____
 Induction Dose: Inject 10mg/kg SQ every 2 weeks for first 3 doses
 Maintenance Dose: Inject 10mg/kg SQ every 4 weeks
QTY: _____ # of vials Refill: _____ If applicable, enroll patient in BENLYSTA Connects

OTHER
SIG _____ QTY: _____ Refill: _____

Prescriber's Name / Practice _____ Office Contact _____
Address _____ Suite# _____ City _____ State _____ Zip _____
Tel _____ Fax _____ Email _____
License# _____ NPI# _____ UPIN# _____ DEA# _____
Prescriber's Signature (signature required. NO STAMPS) _____ Date _____

L21 IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.